OncoSignal
Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma

Ependymoma

Posterior fossa group A and ZFTA-fusion tumours, where surgery and radiotherapy remain the only standard.

Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:11 UTC. Every row links to its source record.

Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.

Phase advances
0
since 2026-07-14
New Ph2+ trials
0
Results posted
0
Readouts due
2
primary completion reached
Trial papers
0
PubMed, last 60 days
  1. Readout due
    Readout due: NCT06521567 reached primary completion

    GlaxoSmithKline. A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

  2. Readout due
    Readout due: NCT04049669 reached primary completion

    Theodore S. Johnson. Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG

A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.